Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

252 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S. Licciardello MP, et al. Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29. Oncogene. 2015. PMID: 25263445
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. Grebien F, et al. Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046. Cell. 2011. PMID: 22000011 Free PMC article.
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. Hantschel O, et al. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7. Proc Natl Acad Sci U S A. 2007. PMID: 17684099 Free PMC article.
252 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page